This site uses cookies to improve your experience. To help us insure we adhere to various privacy regulations, please select your country/region of residence. If you do not select a country, we will assume you are from the United States. Select your Cookie Settings or view our Privacy Policy and Terms of Use.
Cookie Settings
Cookies and similar technologies are used on this website for proper function of the website, for tracking performance analytics and for marketing purposes. We and some of our third-party providers may use cookie data for various purposes. Please review the cookie settings below and choose your preference.
Used for the proper function of the website
Used for monitoring website traffic and interactions
Cookie Settings
Cookies and similar technologies are used on this website for proper function of the website, for tracking performance analytics and for marketing purposes. We and some of our third-party providers may use cookie data for various purposes. Please review the cookie settings below and choose your preference.
Strictly Necessary: Used for the proper function of the website
Performance/Analytics: Used for monitoring website traffic and interactions
Asembia’s SpecialtyPharmacy Summit 2022. Asembia's SpecialtyPharmacy Summit 2022 is back! This is a must-attend event for anyone connected to specialtypharmacy. Plus, Doug Long from IQVIA and I will again lead the Featured Session, titled The SpecialtyPharmacy Industry Update and Outlook.
Licenses for our DCI reports are regularly purchased by nearly every company involved in the drug channel: pharmaceuticalmanufacturers, wholesalers, pharmacists, pharmacy owners, hospitals, buyers, benefit managers, managed care executives, policy analysts, investors, consultants, and more.
ProxsysRx has optimized dozens of 340B programs — generating tens of millions in savings & revenue for the health systems we serve — and the most common question we receive from interested hospitals is, “What’s our 340B network realistically worth?”
reviews the evolving specialtypharmacy industry and discusses emerging challenges from direct distribution models that bypass wholesale distribution. The notable new material in this 2023-24 edition includes: New data about commercial pricing and reimbursement for provider-administered biosimilars appears in Section 3.2.2.
Hospitals and health systems maintain formularies of products that they will stock in the hospitalpharmacy and administer to inpatients. Health insurance providers do the same, and usually outsource this function to Pharmacy Benefit Managers. . ” That seems like the more likely scenario here - to quote Dr.
We organize all of the trending information in your field so you don't have to. Join 11,000+ users and stay up to date on the latest articles your peers are reading.
You know about us, now we want to get to know you!
Let's personalize your content
Let's get even more personalized
We recognize your account from another site in our network, please click 'Send Email' below to continue with verifying your account and setting a password.
Let's personalize your content